Suramin: a potential therapy for diabetic nephropathy.

To determine whether delayed administration of a single dose of suramin, a drug that has been used extensively in humans to treat trypanosomiasis, attenuates renal injury in a leptin receptor deficient C57BLKS/J db/db type 2 diabetic nephropathy (T2DN) mouse model.Groups of female non-diabetic (cont...

Full description

Bibliographic Details
Main Authors: Midhun C Korrapati, Lauren A Howell, Brooke E Shaner, Judit K Megyesi, Leah J Siskind, Rick G Schnellmann
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3767615?pdf=render
id doaj-89bd3183f4a34945ade783ba141ee564
record_format Article
spelling doaj-89bd3183f4a34945ade783ba141ee5642020-11-25T01:51:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0189e7365510.1371/journal.pone.0073655Suramin: a potential therapy for diabetic nephropathy.Midhun C KorrapatiLauren A HowellBrooke E ShanerJudit K MegyesiLeah J SiskindRick G SchnellmannTo determine whether delayed administration of a single dose of suramin, a drug that has been used extensively in humans to treat trypanosomiasis, attenuates renal injury in a leptin receptor deficient C57BLKS/J db/db type 2 diabetic nephropathy (T2DN) mouse model.Groups of female non-diabetic (control) db/m and diabetic db/db mice of 8 and 16 weeks of age, respectively, were treated with suramin (10 mg/kg) or saline i.v. All animals were euthanized one week later. Measurements in mice 1 week following treatment included the following: body weight; blood glucose; urinary protein excretion; pathological lesions in glomeruli and proximal tubules; changes in protein expression of pro-inflammatory transcription factor nuclear factor κB (NF-κB) and intracellular adhesion molecule-1 (ICAM-1), profibrotic transforming growth factor-β1 (TGF-β1), phospho-SMAD-3 and alpha-smooth muscle actin (α-SMA); and immunohistochemical analysis of leukocyte infiltration and collagen 1A2 (COL1A2) deposition.Immunoblot analysis revealed increased NF-κB, ICAM-1, TGF-β1, phospho-SMAD-3, and α-SMA proteins in both 9 and 17 week db/db mice as compared to db/m control mice. Immunohistochemical analysis revealed moderate leukocyte infiltration and collagen 1A2 (COL1A2) deposition in 9 week db/db mice that was increased in the 17 week db/db mice. Importantly, suramin significantly decreased expression of all these markers in 9 week db/db mice and partially decreased in 17 week db/db mice without altering body weight, blood glucose or urinary protein excretion. There was no difference in creatinine clearance between 9 week db/m and db/db mice ± suramin. Importantly, in the 17 week db/db mice suramin intervention reversed the impaired creatinine clearance and overt histological damage.Delayed administration of a single dose of suramin in a model of T2DN attenuated inflammation and fibrosis as well as improved renal function, supporting the use of suramin in T2DN.http://europepmc.org/articles/PMC3767615?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Midhun C Korrapati
Lauren A Howell
Brooke E Shaner
Judit K Megyesi
Leah J Siskind
Rick G Schnellmann
spellingShingle Midhun C Korrapati
Lauren A Howell
Brooke E Shaner
Judit K Megyesi
Leah J Siskind
Rick G Schnellmann
Suramin: a potential therapy for diabetic nephropathy.
PLoS ONE
author_facet Midhun C Korrapati
Lauren A Howell
Brooke E Shaner
Judit K Megyesi
Leah J Siskind
Rick G Schnellmann
author_sort Midhun C Korrapati
title Suramin: a potential therapy for diabetic nephropathy.
title_short Suramin: a potential therapy for diabetic nephropathy.
title_full Suramin: a potential therapy for diabetic nephropathy.
title_fullStr Suramin: a potential therapy for diabetic nephropathy.
title_full_unstemmed Suramin: a potential therapy for diabetic nephropathy.
title_sort suramin: a potential therapy for diabetic nephropathy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description To determine whether delayed administration of a single dose of suramin, a drug that has been used extensively in humans to treat trypanosomiasis, attenuates renal injury in a leptin receptor deficient C57BLKS/J db/db type 2 diabetic nephropathy (T2DN) mouse model.Groups of female non-diabetic (control) db/m and diabetic db/db mice of 8 and 16 weeks of age, respectively, were treated with suramin (10 mg/kg) or saline i.v. All animals were euthanized one week later. Measurements in mice 1 week following treatment included the following: body weight; blood glucose; urinary protein excretion; pathological lesions in glomeruli and proximal tubules; changes in protein expression of pro-inflammatory transcription factor nuclear factor κB (NF-κB) and intracellular adhesion molecule-1 (ICAM-1), profibrotic transforming growth factor-β1 (TGF-β1), phospho-SMAD-3 and alpha-smooth muscle actin (α-SMA); and immunohistochemical analysis of leukocyte infiltration and collagen 1A2 (COL1A2) deposition.Immunoblot analysis revealed increased NF-κB, ICAM-1, TGF-β1, phospho-SMAD-3, and α-SMA proteins in both 9 and 17 week db/db mice as compared to db/m control mice. Immunohistochemical analysis revealed moderate leukocyte infiltration and collagen 1A2 (COL1A2) deposition in 9 week db/db mice that was increased in the 17 week db/db mice. Importantly, suramin significantly decreased expression of all these markers in 9 week db/db mice and partially decreased in 17 week db/db mice without altering body weight, blood glucose or urinary protein excretion. There was no difference in creatinine clearance between 9 week db/m and db/db mice ± suramin. Importantly, in the 17 week db/db mice suramin intervention reversed the impaired creatinine clearance and overt histological damage.Delayed administration of a single dose of suramin in a model of T2DN attenuated inflammation and fibrosis as well as improved renal function, supporting the use of suramin in T2DN.
url http://europepmc.org/articles/PMC3767615?pdf=render
work_keys_str_mv AT midhunckorrapati suraminapotentialtherapyfordiabeticnephropathy
AT laurenahowell suraminapotentialtherapyfordiabeticnephropathy
AT brookeeshaner suraminapotentialtherapyfordiabeticnephropathy
AT juditkmegyesi suraminapotentialtherapyfordiabeticnephropathy
AT leahjsiskind suraminapotentialtherapyfordiabeticnephropathy
AT rickgschnellmann suraminapotentialtherapyfordiabeticnephropathy
_version_ 1724998292372193280